U.S. markets close in 55 minutes
  • S&P 500

    3,582.81
    +25.27 (+0.71%)
     
  • Dow 30

    29,644.16
    +380.68 (+1.30%)
     
  • Nasdaq

    11,905.56
    +50.59 (+0.43%)
     
  • Russell 2000

    1,820.92
    +35.58 (+1.99%)
     
  • Crude Oil

    42.94
    +0.52 (+1.23%)
     
  • Gold

    1,835.70
    -36.70 (-1.96%)
     
  • Silver

    23.63
    -0.73 (-3.01%)
     
  • EUR/USD

    1.1853
    -0.0010 (-0.08%)
     
  • 10-Yr Bond

    0.8550
    +0.0260 (+3.14%)
     
  • GBP/USD

    1.3327
    +0.0036 (+0.27%)
     
  • USD/JPY

    104.4610
    +0.6330 (+0.61%)
     
  • BTC-USD

    18,398.62
    -56.12 (-0.30%)
     
  • CMC Crypto 200

    363.98
    +2.55 (+0.71%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    25,527.37
    -106.93 (-0.42%)
     

BIIB Shareholder Notification: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

·2 min read

NEW YORK, NY / ACCESSWIRE / November 13, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ:BIIB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Biogen securities pursuant between October 22, 2019 and November 6, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/biib.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab's effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the FDA's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/biib or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Biogen you have until January 12, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/616616/BIIB-Shareholder-Notification-Bronstein-Gewirtz-Grossman-LLC-Notifies-Biogen-Inc-Investors-of-Class-Action-and-Encourages-Shareholders-to-Contact-the-Firm